Detalhe da pesquisa
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048557
2.
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.
Int J Mol Sci
; 25(3)2024 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38338802
3.
Maintenance therapy in multiple myeloma: Two is not always better than one.
Br J Haematol
; 201(2): 181-182, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541138
4.
Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre.
Br J Haematol
; 201(3): 432-442, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36648095
5.
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review.
Cancers (Basel)
; 16(8)2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38672557
6.
Current Main Topics in Multiple Myeloma.
Cancers (Basel)
; 15(8)2023 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37190132
7.
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences.
Cancers (Basel)
; 15(11)2023 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296910
8.
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment.
Pharmaceuticals (Basel)
; 16(11)2023 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38004493
9.
An update on novel multiple myeloma targets.
Expert Rev Hematol
; 15(6): 519-537, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35640130
10.
Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
Cells
; 11(4)2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35203257
11.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 40(27): 3120-3131, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35666982
12.
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Drug Des Devel Ther
; 15: 2401-2415, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34103900
13.
Novel Experimental Drugs for Treatment of Multiple Myeloma.
J Exp Pharmacol
; 13: 245-264, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33727866
14.
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study.
Leuk Lymphoma
; 62(8): 1897-1906, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33733993
15.
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Front Oncol
; 10: 624661, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33680948
16.
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment.
Pharmaceuticals (Basel)
; 13(12)2020 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33260960
17.
Developments in consolidation and maintenance strategies in post-remission multiple myeloma.
Expert Rev Hematol
; 13(4): 351-362, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162982
18.
Editorial: Reviews in hematologic malignancies.
Front Oncol
; 12: 1105523, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36620571